Evidence map›Paper›PMID 32214477›Full record

ArticleMolecular biology2017

Next-Generation Techniques for Discovering Human Monoclonal Antibodies.

A A Lushova, M G Biazrova, A G Prilipov, G K Sadykova, T A Kopylov, A V Filatov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Therapeutic Antibodies: An Overview.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  3. Review
  4. Considerations for the Design of Antibody-Based Therapeutics.Journal of pharmaceutical sciences · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A A Lushova1Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, 115478 Russia.
M G Biazrova1Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, 115478 Russia.
A G Prilipov2Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
G K Sadykova2Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
T A Kopylov3Orekhovich Institute of Biomedical Chemistry, Moscow, 119121 Russia.
A V Filatov1Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, 115478 Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies have found wide applications in the treatment of cancer, as well as of autoimmune, infectious, and other diseases. Several dozen new antibodies are currently undergoing different stages of clinical trials, and some of them will soon be added to the list of immunotherapeutic drugs. Most of these antibodies have been generated using hybridoma technology or a phage display. In recent years, new methods of obtaining human monoclonal antibodies have been actively developing. These methods rely on sequencing immunoglobulin genes from B lymphocytes, as well as on the creation of antibody-secreting stable B-cell lines. The term

Indexed as

B-cell immortalizationhuman monoclonal antibodiesimmunoglobulinsnext-generation sequencing

Identifiers

PMID32214477
PMCPMC7088925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.